Results 31 to 40 of about 61,573 (234)

Evaluation of synergistic effect of tazobactam with meropenem and ciprofloxacin against multi-drug resistant Acinetobacter baumannii isolated from burn patients in Tehran

open access: yesGMS Hygiene and Infection Control, 2019
Background: is an increasingly important cause of nosocomial infections worldwide. In addition to the intrinsic resistance of to many antibiotics, available treatment approaches with older antibiotics are significantly associated with an increase in ...
Valadan Tahbaz, Sahel   +3 more
doaj   +1 more source

Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon

open access: yesJournal of Infection in Developing Countries, 2020
Introduction: In view of the continuous rise in Gram-negative bacterial resistance and limited treatment options, Ceftolozane/tazobactam (C/T) is a newly introduced antimicrobial agent in Lebanon for its demonstrated activity against resistant Gram ...
George F Araj   +3 more
doaj   +1 more source

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study

open access: yesBrazilian Journal of Infectious Diseases, 2020
Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens.
Felipe Francisco Tuon   +4 more
doaj   +1 more source

SINGLE-DOSE TOXICITY STUDIES OF TAZOBACTAM/PIPERACILLIN AND TAZOBACTAM

open access: yesThe Journal of Toxicological Sciences, 1994
Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor. Tazobactam/Piperacillin (TAZ/PIPC) is a formulation consisting of TAZ and PIPC in a ratio of 1:4. Singe-dose toxicity studies in TAZ/PIPC and TAZ were carried out using mice and rats of both sexes and male dogs. The results were as follows. 1.
HAYASHI, Taiji   +7 more
openaire   +3 more sources

Cross-Canada Survey of Resistance of 2747 Aerobic Blood Culture Isolates to Piperacillin/Tazobactam and Other Antibiotics

open access: yes, 1998
OBJECTIVE: To compare the activity of piperacillin/tazobactam with that of other broad parenteral antibiotics against aerobic and facultative anaerobic blood culture isolates in a Canada-wide ...
Kevin R Forward   +5 more
core   +1 more source

Study of the Comparative Activity of Piperacillin/Tazobactam with Currently Available Antibiotics against 8206 Aerobic Isolates [PDF]

open access: yes, 1997
OBJECTIVES: To compare the activity of piperacillin-tazobactam with piperacillin and other parenterally administered antibiotics against aerobic Gram-negative bacilli and Gram-positive cocci isolated from across Canada, and to determine the prevalence of
Kevin R Forward   +6 more
core   +1 more source

Pulmonary penetration of piperacillin and tazobactam in critically ill patients.

open access: yes, 2014
Pulmonary infections in critically ill patients are common and are associated with high morbidity and mortality. Piperacillin–tazobactam is a frequently used therapy in critically ill patients with pulmonary infection.
Goodwin, J   +7 more
core   +1 more source

Pharmacokinetics of Piperacillin and Tazobactam.

open access: yes, 2016
Pharmacokinetics of Piperacillin and Tazobactam.
Omar Vesga (248534)   +4 more
core   +1 more source

The impact of medication shortages on paediatric care: A retrospective impact analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Medication shortages are a growing global concern, with potentially greater consequences in paediatric patients because of the limited availability of safe, evidence‐based and appropriately formulated medication. This study aimed to evaluate the impact of medication shortages on paediatric patients by assessing the suitability and safety of ...
Maaike Johanna Rutten ‐ van Kranenburg   +6 more
wiley   +1 more source

Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

open access: yesJournal of Global Antimicrobial Resistance, 2021
: Objectives: Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. Here we report the use of ceftolozane/tazobactam in Canada using a national registry. Methods: The CLEAR registry uses
George G. Zhanel   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy